Palbociclib 100mg: Clinical Trials

2 completed, 1 terminated. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Completed 1, Terminated 1
Phase 2	2	Completed 1, Terminated 1

Follow Palbociclib 100mg: new trials by email Literature Review of Palbociclib 100mg trials Research Report on Palbociclib 100mg

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Palbociclib 75mg, Letrozole 2.5mg, T-DM1 - HER2-positive Breast Cancer, Breast Cancer Metastatic	Phase 1 / Phase 2	Terminated	University of Kansas Medical Center	3	2018-10-15	2024-03-05
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor - Breast Cancer	Phase 2	Completed	Canadian Cancer Trials Group	180	2016-04-08	2026-04-13
A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg - Healthy	Phase 1	Completed	Pfizer	27	2014-03-01	2014-06-24

Conditions studied

Breast Neoplasms (1)

Sponsors

Canadian Cancer Trials Group (1)  ·  Pfizer (1)  ·  University of Kansas Medical Center (1)

Countries

United States (2)  ·  Canada (1)

Top investigators

Anil A. Joy (1)  ·  Lauren Nye, MD (1)

Results publications

PMID 41123599